Literature DB >> 10235519

Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome.

C J Yeo1, J L Cameron, T A Sohn, J Coleman, P K Sauter, R H Hruban, H A Pitt, K D Lillemoe.   

Abstract

OBJECTIVE: This prospective, randomized, single-institution trial was designed to evaluate the end points of mortality, morbidity, and survival in patients undergoing standard versus radical (extended) pancreaticoduodenectomy (including distal gastrectomy and retroperitoneal lymphadenectomy). SUMMARY BACKGROUND DATA: Numerous retrospective reports and one prospective randomized trial have suggested that the performance of an extended lymphadenectomy in association with a pancreaticoduodenal resection may improve long-term survival for some patients with pancreatic and other periampullary adenocarcinomas. Many of these previously published studies can be criticized for their retrospective and nonrandomized designs, for the inclusion of nonconcurrent control groups, and for their small numbers.
METHODS: Between April 1996 and December 1997, 114 patients with periampullary adenocarcinoma were enrolled in an ongoing, prospective, randomized trial at The Johns Hopkins Hospital. After intraoperative verification of completely resected periampullary adenocarcinoma, the patients were randomized to receive either a standard pancreaticoduodenectomy (removing only the peripancreatic lymph nodes en bloc with the specimen) or a radical pancreaticoduodenectomy (standard resection plus distal gastrectomy and retroperitoneal lymphadenectomy). All pathology specimens were reviewed and categorized. The postoperative morbidity, mortality, and short-term outcomes were examined.
RESULTS: Of the 114 patients randomized, 56 underwent a standard pancreaticoduodenectomy and 58 a radical pancreaticoduodenectomy. The two groups were statistically similar with regard to age and gender, but there was a higher percentage of white patients in the radical group. All the patients in the radical group underwent distal gastric resection, whereas 86% of the patients in the standard group underwent pylorus preservation. The mean operative time in the radical group was 6.8 hours, compared with 6.2 hours in the standard group. There were no significant differences between the two groups with respect to the intraoperative blood loss, transfusion requirements, location of primary tumor, mean tumor size, positive lymph node status, or positive margin status. There were three deaths in the standard group and two in the radical group. The complication rates were 34% for the standard group and 40% for the radical group. Patients undergoing radical resection had a higher incidence of early delayed gastric emptying but had similar rates of other complications, such as pancreatic fistula, wound infection, intraabdominal abscess, and need for reoperation. The mean total number of lymph nodes resected was higher in the radical group. Of the 58 patients in the radical group, only 10% had metastatic carcinoma in the resected retroperitoneal lymph nodes, and none of those patients had the retroperitoneal nodes as the only site of lymph node involvement. The 1-year actuarial survival rate for patients surviving the immediate postoperative periods was 77% for the standard resection group and 83% for the radical resection group.
CONCLUSIONS: These data demonstrate that radical pancreaticoduodenectomy (with the addition of a distal gastrectomy and extended retroperitoneal lymphadenectomy to a standard pancreaticoduodenectomy) can be performed with similar morbidity and mortality to standard pancreaticoduodenectomy. However, the survival data are not sufficiently mature and the numbers of patients enrolled are not adequate to allow firm conclusions to be drawn regarding survival benefit.

Entities:  

Mesh:

Year:  1999        PMID: 10235519      PMCID: PMC1420805          DOI: 10.1097/00000658-199905000-00003

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  39 in total

1.  Surgical curability and prognosis for standard versus extended resection for T1 carcinoma of the pancreas.

Authors:  K Satake; H Nishiwaki; H Yokomatsu; Y Kawazoe; K Kim; A Haku; K Umeyama; I Miyazaki
Journal:  Surg Gynecol Obstet       Date:  1992-09

2.  Clinical experience with regional pancreatectomy for adenocarcinoma of the pancreas.

Authors:  W F Sindelar
Journal:  Arch Surg       Date:  1989-01

Review 3.  Recent advances in pancreatic cancer.

Authors:  J G Fortner
Journal:  Surg Clin North Am       Date:  1974-08       Impact factor: 2.741

4.  Regional resection of cancer of the pancreas: a new surgical approach.

Authors:  J G Fortner
Journal:  Surgery       Date:  1973-02       Impact factor: 3.982

5.  Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head.

Authors:  O Ishikawa; H Ohhigashi; Y Sasaki; T Kabuto; I Fukuda; H Furukawa; S Imaoka; T Iwanaga
Journal:  Ann Surg       Date:  1988-08       Impact factor: 12.969

6.  Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas.

Authors:  T Manabe; G Ohshio; N Baba; T Miyashita; N Asano; K Tamura; K Yamaki; A Nonaka; T Tobe
Journal:  Cancer       Date:  1989-09-01       Impact factor: 6.860

7.  Regional pancreatectomy: en bloc pancreatic, portal vein and lymph node resection.

Authors:  J G Fortner; D K Kim; A Cubilla; A Turnbull; L D Pahnke; M E Shils
Journal:  Ann Surg       Date:  1977-07       Impact factor: 12.969

8.  Prognostic indicators for survival after resection of pancreatic adenocarcinoma.

Authors:  R J Geer; M F Brennan
Journal:  Am J Surg       Date:  1993-01       Impact factor: 2.565

9.  Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma.

Authors:  F Tian; H E Appert; J Myles; J M Howard
Journal:  Ann Surg       Date:  1992-04       Impact factor: 12.969

10.  Adenocarcinoma of the duodenum: factors influencing long-term survival.

Authors:  T A Sohn; K D Lillemoe; J L Cameron; H A Pitt; H S Kaufman; R H Hruban; C J Yeo
Journal:  J Gastrointest Surg       Date:  1998 Jan-Feb       Impact factor: 3.267

View more
  109 in total

1.  Whipple or pylorus preservation? A critical reappraisal and some new insights into pancreaticoduodenectomy.

Authors:  J L Cameron
Journal:  Ann Surg       Date:  2000-03       Impact factor: 12.969

2.  The Johns Hopkins experience with pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma.

Authors:  C J Yeo
Journal:  J Gastrointest Surg       Date:  2000 May-Jun       Impact factor: 3.452

3.  Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy?

Authors:  M W Büchler; C Bassi; A Fingerhut; I Klempa
Journal:  Ann Surg       Date:  2001-08       Impact factor: 12.969

Review 4.  Pancreatic cancer: from genes to patient care.

Authors:  R H Hruban
Journal:  J Gastrointest Surg       Date:  2001 Nov-Dec       Impact factor: 3.452

5.  Extended pancreatic resections and lymphadenectomy: An appraisal of the current evidence.

Authors:  Shailesh V Shrikhande; Savio G Barreto
Journal:  World J Gastrointest Surg       Date:  2010-02-27

6.  Pancreatic adenocarcinoma.

Authors:  Margaret A Tempero; J Pablo Arnoletti; Stephen Behrman; Edgar Ben-Josef; Al B Benson; Jordan D Berlin; John L Cameron; Ephraim S Casper; Steven J Cohen; Michelle Duff; Joshua D I Ellenhorn; William G Hawkins; John P Hoffman; Boris W Kuvshinoff; Mokenge P Malafa; Peter Muscarella; Eric K Nakakura; Aaron R Sasson; Sarah P Thayer; Douglas S Tyler; Robert S Warren; Samuel Whiting; Christopher Willett; Robert A Wolff
Journal:  J Natl Compr Canc Netw       Date:  2010-09       Impact factor: 11.908

Review 7.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

Review 8.  Systemic Review of the Feasibility and Advantage of Minimally Invasive Pancreaticoduodenectomy.

Authors:  Chien-Hung Liao; Yu-Tung Wu; Yu-Yin Liu; Shang-Yu Wang; Shih-Ching Kang; Chun-Nan Yeh; Ta-Sen Yeh
Journal:  World J Surg       Date:  2016-05       Impact factor: 3.352

Review 9.  Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?

Authors:  H G Smeenk; T C K Tran; J Erdmann; C H J van Eijck; J Jeekel
Journal:  Langenbecks Arch Surg       Date:  2004-05-14       Impact factor: 3.445

10.  Magnetic resonance imaging monitors physiological changes with antihedgehog therapy in pancreatic adenocarcinoma xenograft model.

Authors:  Alexander R Guimaraes; Elena Rakhlin; Ralph Weissleder; Sarah P Thayer
Journal:  Pancreas       Date:  2008-11       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.